Community Considerations in Relapsed/Refractory Multiple Myeloma: Current and Developing Anti-BCMA Therapies
RELEASED DATE: January 18, 2023
EXPIRATION DATE: January 27, 2024
This enduring activity has been designed for community-based hematology-oncologists, nurse practitioners, and physician assistants to ensure confidence in the management of relapsed/refractory multiple myeloma. It discusses the mechanisms of resistance and characteristics of refractory disease in patients with multiple myeloma; review the mechanisms of action of both current and emerging therapies in the treatment of patients with relapsing/refractory multiple myeloma; and lastly evaluates the clinical data for developing agents in the management of patients with late relapse/refractory multiple myeloma.